IceCure Medical Offers Alternative to Surgery in Early Breast Cancer

IceCure Medical Ltd. (Nasdaq: ICCM) is offering breast cancer patients a safe and effective outpatient alternative to surgery with an innovative cryotherapy treatment. IceCure’s share price rose nearly 55% in intraday trading following the news.

Data from a new study, which concluded that cryoablation could be an alternative treatment to surgery for breast cancer in patients who reject surgery, was presented at the European Society of Breast Imaging in Spain this week.

IceCure’s ProSense® System is a minimally-invasive cryoablation technology that destroys tumors by freezing as an alternative to surgical tumor removal.

IceCure CEO, Eyal Shamir, said, “Doctors around the world are using ProSense with women who want an alternative to surgery for early- stage breast cancer, and it’s highly encouraging to see these physicians publish and share their results with the medical community. These data are very much in line with the interim results of our ICE3 study, the largest of its kind in the U.S., which is expected to conclude in the first quarter of 2024.”

Highlights

A study at University Hospital Lucus Augusti in Lugo, Spain, used ProSense for cryoablation treatment of 31 patients with early-stage breast cancer who declined surgery, the current standard of care. No major complications were seen and the procedure was well tolerated by all patients.

ProSense is approved for the treatment of breast cancer throughout the European Union

Breast cancer is the most commonly diagnosed malignant neoplasm worldwide. Surgery is the standard of care for early-stage breast cancer, some patients, most of them elderly, decline standard of care surgery and prefer a less invasive option.

IceCure believes that ProSense could potentially have an impact on the way cancers of the kidney, lung, and thyroid gland are treated.

About IceCure Medical

IceCure Medical (Nasdaq: ICCM) develops and markets ProSense®, an advanced liquid-nitrogen-based cryoablation therapy for the treatment of tumors (benign and cancerous) by freezing, with the primary focus areas being breast, kidney, bone and lung cancer. Its minimally invasive technology is a safe and effective alternative to hospital surgical tumor removal that is easily performed in a relatively short procedure. The system is marketed and sold worldwide for the indications cleared and approved to date including in the U.S., Europe, and China.